Page 10 - Ipca Labs News Today

Five such companies which have firmed up their initial public offering (IPO) plans are Glenmark Lifesciences, a fully-owned arm of Glenmark Pharmaceuticals, the city-based bulk drugs firm Supriya Lifesciences, drug formulations firm Windlass Biotech, Bain Capital-backed Emcure Pharma and CX Partners-funded Veeda Clinical Research. According to investment-bankers, they are planning to mop up over Rs 7,000 crore in primary share sales.

Adani Transmission, Cipla, GAIL, Gujarat Gas, Honeywell Automation, Adani Power, REC, Aditya Capital, Ipca Laps, Tata Chemicals and Escorts will announce quarterly earnings today.

Asian shares were trading with mild gains on Thursday, shrugging off the worries about coronavirus infections and mixed overnight trade on Wall Street. MSCIs broadest index of Asia-Pacific shares outside Japan was up by 0.15 per cent.

While the Covid-19 situation is improving in India, other Asian countries are witnessing a rise in infections. This might impact sentiments for Asian markets in general, said an analyst.

Read more about Nifty trades above 15,400; pharma stocks correct on Business Standard. At 10:25 IST, the barometer index, the S&P BSE Sensex, was up 252.09 points or 0.49% at 51,367.40. The Nifty 50 index gained 89.85 points or 0.59% to 15,427.70. The Nifty hit a record high level of 15,455.55 in early trade today.

Ipca Labs Q4 profit up 94 pc at Rs 161 cr Ipca Labs Q4 profit up 94 pc at Rs 161 cr New Delhi, May 28: Drug firm Ipca Laboratories on Friday reported 94.09 per cent rise in consolidated net profit at Rs 161.20 crore for March quarter 2020-21 mainly on account of higher sales and reduction in expenses. The company posted a net profit of Rs 83.05 crore for the same period a year ago, Ipca Labs said in a filing to BSE. Total income stood at Rs 1,134.58 crore in the quarter under review. It was Rs...

Read more about Drug firm Ipca Laboratories fourth quarter profit up 94% at Rs 161 crore on Business Standard. Shares of Ipca Laboratories were trading at Rs 2,132.30 per scrip on BSE, down 3.06 per cent from the previous close.

Amidst the raging second wave of the COVID-19 pandemic and many fearing a third wave, the healthcare sector is in the limelight for the second consecutive year as several pharma and life sciences companies are lined up to tap the equity markets through IPOs over the next few months, according to investment bankers. Five such companies which have firmed up their initial public offering (IPO) plans are Glenmark Lifesciences, a fully-owned arm of Glenmark Pharmaceuticals, the city-based bulk dru...

Covid pushes Indias Pharma industry growth to 59% in April ​ By IANS | ​ 2 Views Indias pharma exports surge as tide turns against China Image Source: IANS News Despite the widespread use of oral contraceptives (OCPs) by women, many are not aware that it may impair their ability to recognise others emotional expressions, which may have serious consequences in interpersonal contexts, suggests a new study. Image Source: IANS News New Delhi, May 15 : The fresh wave of Covid-19 in the country...

The fresh wave of Covid-19 in the country has pushed up sales of medicines and resulted in exponential growth for the pharmaceutical sector.